TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00056966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506
Description: Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day-8 through Day-5 30 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day-8 through Day-5 30 mg/m2

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Day-1 single dose 450 cGy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Day-1 single dose 450 cGy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count \>2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count \>2 x 108/kg) will be substituted.
Study: NCT01780675

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Prophylactic Cranial Irradiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Hippocampal Avoidance PCI
Study: NCT00754000

Intervention type: OTHER
Intervention: Observation
Description: AE monitoring and EPIC QOL survey
Study: NCT02972359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid
Description: Neridronic acid administered as intravenous infusion.
Study: NCT04518813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Investigational Medical Device collecting Raman data from tissue
Study: NCT02928172

Intervention type: DEVICE
Group type: OTHER
Intervention: qCON-qNOX
Description: Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor

Intervention type: DEVICE
Group type: OTHER
Intervention: BIS
Description: Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
Study: NCT00459524

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires taking about 30 minutes to complete.

Intervention type: BEHAVIORAL
Intervention: Neurocognitive Testing
Description: Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
Study: NCT01432769

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: dietary supplement high in energy and protein
Description: patients in the standardized diet will receive extra 500 kcal from the dietary supplement
Study: NCT03366506

Intervention type: OTHER
Intervention: Observation
Study: NCT03539952

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillamine (D1-W12)
Description: Penicillamine during baseline period (D1-W12)
Study: NCT00484367

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent group therapy
Description: Adolescent group therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transitional family therapy
Description: Transitional family therapy
Study: NCT03539952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penicillamine (D1-W12)
Description: Penicillamine during baseline period (D1-W12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TETA 4HCL (W12-60)
Description: TETA 4HCL during post randomisation and 1st extension period (W12-W60)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Penicillamine (W12-W60)
Description: Penicillamine during rondomisation and 1st extension period period (W12-W60)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TETA 4HCL (60-<W108)
Description: TETA 4HCL during 2nd extension period (W60-\<W108)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TETA 4HCL (60-<W108)
Description: TETA 4HCL during 2nd extension period (W60-\<W108)
Study: NCT01541059

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Injection of saline solution into the vestibular capsule of each tooth to be extracted.
Study: NCT02469584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: small stitch anterior colporrhaphy
Description: A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
Study: NCT00324272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin Sealant (Tisseel) used in the Experimental Arm.
Description: For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant (Tisseel) used in the Experimental Arm.
Description: For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fibrin Sealant (Tisseel) used in the Experimental Arm.
Description: For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant (Tisseel) used in the Experimental Arm.
Description: For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.~For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects).
Study: NCT03505957

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SafeBreak Vascular
Description: SafeBreak Vascular will be installed in all the IV lines of consenting participants for up to 7 days.
Study: NCT03908086

Intervention type: OTHER
Intervention: Risk factors in RA cohort

Intervention type: OTHER
Intervention: Risk factors in general population
Study: NCT04348136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR-141
Description: IV infusion, 2.0 mg/kg/week
Study: NCT02798445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAPIRS
Description: Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL
Description: Multilayer bandages and wound care
Study: NCT06465355

Intervention type: PROCEDURE
Group type: OTHER
Intervention: pharyngo-esophageal high-resolution manometry
Description: The high resolution manometry (HRM) catheter will be inserted through the more patent nares and positioned such that it covers the pharynx and the esophagus. Affixed to the high resolution catheter will be a single lumen, end-hole catheter (length: 90 cm, outside diameter: 1.58 mm) wherein the end hole of the tube will be secured at a fixed pharyngeal site on the HRM catheter and the other end of the tube will be connected to a stopcock so that the tube may be either open or closed to atmospheric pressure. 3. Study subjects will be asked to swallow their ambient saliva ten times with the stopcock open and ten times with the stopcock closed. There is a 30 second interval between swallows.
Study: NCT04684160

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed-bearing TKA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Study: NCT01375439

Intervention type: OTHER
Group type: OTHER
Intervention: Active search of lower genital tract infections
Description: Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
Study: NCT02583360

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Combined testing (diagnostic VFSS + research HRM) + Parent Preferred Therapy
Description: Addition of research HRM along with diagnostic VFSS with parental choice of therapy
Study: NCT01541059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
Study: NCT00329459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan succinate/naproxen sodium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo to match
Study: NCT04430868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle redesign program
Description: In this group, it starts with health education, the participants then change their opinions and experience health activities, and it ends with discussion and sharing their experience.
Study: NCT01602744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: STOPP/START screening tools for medication intervention
Description: In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
Study: NCT00257322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250ug/m\^2 SQ QD with a cap of 500mcg SQ QD
Study: NCT04207125

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multilevel psychotherapeutic intervention programme
Description: Part 1: Educational Training and Mentoring After transferring the patient from the intensive care unit to the transplant surgery unit, nurses are planning a nursing diagnosis called therapy recommendations and coping strategies, effective implementation. 3 days after the transfer, nurses start to give information twice a day (morning and evening) about the medication, which the patients are currently taking. The nurse is also handing out a folder, which contains information about the multilevel intervention programme.~Individual Treatment Approach Patients, who seem to be non-adherent during their outpatient follow-ups, are contacted through the co-investigators for a one-to-one session. The content of this session is to promote patients engagement in self-management of their chronic illness. The goal of the treatment is to improve the individual's ability to manage symptoms, treatments, physical and psychosocial consequences and lifestyle changes.
Study: NCT03642275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCardia4HF
Description: Participants in the intervention group will receive the Heart Failure Health Storylines mobile app, three connected health devices that interface with the app (Fitbit Charge 2 activity tracker, and FDA-approved Nokia BP monitor and Cardio Body weight scale), and a program of tailored self-care text-messages, in addition to usual care. Participants will be asked to use the app and devices to record and self-monitor their daily symptoms, blood pressure, weight, and physical activity.
Study: NCT00826709

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluID Rapid Influenza Test
Description: The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluID Rapid Influenza Test
Description: The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fluID Rapid Influenza Test
Description: The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
Study: NCT05578560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prehabituation
Description: chemical labyrinthectomy with intratympanically installed gentamicin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D optokinetic stimulation in virtual reality space
Description: 3D optokinetic stimulation via virtual reality goggles with the software designed by Pro-Zeta comp.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular training
Description: vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular training
Description: vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vestibular training
Description: vestibular training program adopted for patients with acute vestibular loss under the supervision of a physical therapist. The program includes gaze stability exercises, smooth pursuit, and saccadic eye movements, and postural exercises to improve balance control and gait stability. Each session lasts around 30 minutes and happened daily for the 7 postoperative days.
Study: NCT00914966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 inhibitor (human) [C1 INH]
Study: NCT01701401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT03693066

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as ozone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine digluconate
Description: In the two-visit indirect pulp therapy, due to reduce the number of bacteria remaining in the cavity, the antimicrobial agents can be used as cavity disinfectants such as chlorhexidine digluconate.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Study: NCT01298076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Anti-VEGF drug for intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Slow-release steroid formulation for intravitreal injection
Study: NCT01000805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
Study: NCT00681395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: once daily for six days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-335
Description: once daily for six days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Once daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Once daily for 6 days
Study: NCT04264520

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PTSD Psychoeducation + Skills Intervention
Description: A brief computer-assisted intervention (psychoeducation + skills) for pregnant women with elevated PTSD symptoms.
Study: NCT03275506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab
Description: Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy - Bevacizumab
Description: Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
Study: NCT04727996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: 120 mg will be administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200 mg will be administered intravenously (IV) once every 3 weeks
Study: NCT01769950

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Choline-PET
Description: Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
Study: NCT03835182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound group
Description: Ultrasound 1 MHz, 1.5 W/cm2 for a total of 10 min applied to the lower back

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short wave diathermy group
Description: SWD frequency of 27.12MHz applied in continuous mode (thermic) applied to the lower back for twenty minutes

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: superficial heat, analgesic physical modality and exercise only
Study: NCT03719001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca channel blocker, CaCl, tetanic stimulus and increase in venous pressure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevidipine
Description: blood pressure will be increased or decreased by using one of six interventions: phenylephrine (alpha-1 agonist), dexmedetomidine (alpha-2 agonist), clevidipine (Ca

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tetanic stimulus
Description: A 5 second 70 mA tetanic stimulus will be applied to elicit peripheral vasoconstriction (stress response)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increased venous pressure
Description: A 5 minute inflation of a noninvasive blood pressure cuff to 30 mmHg to increase venous pressure in the arm with the pulse oximeter probes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Chloride
Description: CaCl will be administered to increase blood pressure and plasma calcium concentration
Study: NCT02916199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cannulation of ampulla of Vater
Description: Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cannulation of ampulla of Vater
Description: Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices